Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.
BACKGROUND: Anticoagulants are more effective than antiplatelet agents at reducing stroke risk in patients with atrial fibrillation, but whether this benefit outweighs the increased risk of bleeding in elderly patients is unknown. We assessed whether warfarin reduced risk of major stroke, arterial e...
| প্রধান লেখক: | , , , , , , |
|---|---|
| বিন্যাস: | Journal article |
| ভাষা: | English |
| প্রকাশিত: |
2007
|
| _version_ | 1826300308759773184 |
|---|---|
| author | Mant, J Hobbs, F Fletcher, K Roalfe, A Fitzmaurice, D Lip, G Murray, E |
| author_facet | Mant, J Hobbs, F Fletcher, K Roalfe, A Fitzmaurice, D Lip, G Murray, E |
| author_sort | Mant, J |
| collection | OXFORD |
| description | BACKGROUND: Anticoagulants are more effective than antiplatelet agents at reducing stroke risk in patients with atrial fibrillation, but whether this benefit outweighs the increased risk of bleeding in elderly patients is unknown. We assessed whether warfarin reduced risk of major stroke, arterial embolism, or other intracranial haemorrhage compared with aspirin in elderly patients. METHODS: 973 patients aged 75 years or over (mean age 81.5 years, SD 4.2) with atrial fibrillation were recruited from primary care and randomly assigned to warfarin (target international normalised ratio 2-3) or aspirin (75 mg per day). Follow-up was for a mean of 2.7 years (SD 1.2). The primary endpoint was fatal or disabling stroke (ischaemic or haemorrhagic), intracranial haemorrhage, or clinically significant arterial embolism. Analysis was by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN89345269. FINDINGS: There were 24 primary events (21 strokes, two other intracranial haemorrhages, and one systemic embolus) in people assigned to warfarin and 48 primary events (44 strokes, one other intracranial haemorrhage, and three systemic emboli) in people assigned to aspirin (yearly risk 1.8%vs 3.8%, relative risk 0.48, 95% CI 0.28-0.80, p=0.003; absolute yearly risk reduction 2%, 95% CI 0.7-3.2). Yearly risk of extracranial haemorrhage was 1.4% (warfarin) versus 1.6% (aspirin) (relative risk 0.87, 0.43-1.73; absolute risk reduction 0.2%, -0.7 to 1.2). INTERPRETATION: These data support the use of anticoagulation therapy for people aged over 75 who have atrial fibrillation, unless there are contraindications or the patient decides that the benefits are not worth the inconvenience. |
| first_indexed | 2024-03-07T05:15:10Z |
| format | Journal article |
| id | oxford-uuid:dcec06ef-9a3d-4e27-8246-8dcc50c4ba56 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:15:10Z |
| publishDate | 2007 |
| record_format | dspace |
| spelling | oxford-uuid:dcec06ef-9a3d-4e27-8246-8dcc50c4ba562022-03-27T09:21:13ZWarfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:dcec06ef-9a3d-4e27-8246-8dcc50c4ba56EnglishSymplectic Elements at Oxford2007Mant, JHobbs, FFletcher, KRoalfe, AFitzmaurice, DLip, GMurray, EBACKGROUND: Anticoagulants are more effective than antiplatelet agents at reducing stroke risk in patients with atrial fibrillation, but whether this benefit outweighs the increased risk of bleeding in elderly patients is unknown. We assessed whether warfarin reduced risk of major stroke, arterial embolism, or other intracranial haemorrhage compared with aspirin in elderly patients. METHODS: 973 patients aged 75 years or over (mean age 81.5 years, SD 4.2) with atrial fibrillation were recruited from primary care and randomly assigned to warfarin (target international normalised ratio 2-3) or aspirin (75 mg per day). Follow-up was for a mean of 2.7 years (SD 1.2). The primary endpoint was fatal or disabling stroke (ischaemic or haemorrhagic), intracranial haemorrhage, or clinically significant arterial embolism. Analysis was by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN89345269. FINDINGS: There were 24 primary events (21 strokes, two other intracranial haemorrhages, and one systemic embolus) in people assigned to warfarin and 48 primary events (44 strokes, one other intracranial haemorrhage, and three systemic emboli) in people assigned to aspirin (yearly risk 1.8%vs 3.8%, relative risk 0.48, 95% CI 0.28-0.80, p=0.003; absolute yearly risk reduction 2%, 95% CI 0.7-3.2). Yearly risk of extracranial haemorrhage was 1.4% (warfarin) versus 1.6% (aspirin) (relative risk 0.87, 0.43-1.73; absolute risk reduction 0.2%, -0.7 to 1.2). INTERPRETATION: These data support the use of anticoagulation therapy for people aged over 75 who have atrial fibrillation, unless there are contraindications or the patient decides that the benefits are not worth the inconvenience. |
| spellingShingle | Mant, J Hobbs, F Fletcher, K Roalfe, A Fitzmaurice, D Lip, G Murray, E Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. |
| title | Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. |
| title_full | Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. |
| title_fullStr | Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. |
| title_full_unstemmed | Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. |
| title_short | Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. |
| title_sort | warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation the birmingham atrial fibrillation treatment of the aged study bafta a randomised controlled trial |
| work_keys_str_mv | AT mantj warfarinversusaspirinforstrokepreventioninanelderlycommunitypopulationwithatrialfibrillationthebirminghamatrialfibrillationtreatmentoftheagedstudybaftaarandomisedcontrolledtrial AT hobbsf warfarinversusaspirinforstrokepreventioninanelderlycommunitypopulationwithatrialfibrillationthebirminghamatrialfibrillationtreatmentoftheagedstudybaftaarandomisedcontrolledtrial AT fletcherk warfarinversusaspirinforstrokepreventioninanelderlycommunitypopulationwithatrialfibrillationthebirminghamatrialfibrillationtreatmentoftheagedstudybaftaarandomisedcontrolledtrial AT roalfea warfarinversusaspirinforstrokepreventioninanelderlycommunitypopulationwithatrialfibrillationthebirminghamatrialfibrillationtreatmentoftheagedstudybaftaarandomisedcontrolledtrial AT fitzmauriced warfarinversusaspirinforstrokepreventioninanelderlycommunitypopulationwithatrialfibrillationthebirminghamatrialfibrillationtreatmentoftheagedstudybaftaarandomisedcontrolledtrial AT lipg warfarinversusaspirinforstrokepreventioninanelderlycommunitypopulationwithatrialfibrillationthebirminghamatrialfibrillationtreatmentoftheagedstudybaftaarandomisedcontrolledtrial AT murraye warfarinversusaspirinforstrokepreventioninanelderlycommunitypopulationwithatrialfibrillationthebirminghamatrialfibrillationtreatmentoftheagedstudybaftaarandomisedcontrolledtrial |